J&J Unit Fights Generic's Bid To Invalidate Cancer Drug Patent
A subsidiary of Johnson & Johnson has hit back at a claim by generic-drug maker Accord Healthcare that its patent for a prostate cancer treatment should be made invalid, denying that...To view the full article, register now.
Already a subscriber? Click here to view full article